Fennec Pharmaceuticals (FENC) said licensing partner Norgine Pharmaceuticals received positive final draft guidance from the National Institute for Health and Care Excellence recommending Pedmarqsi for use in England and Wales to prevent cisplatin-induced hearing loss in patients aged 1 month to 17 years with localized, non-metastatic solid tumors.
"Securing access to Pedmarqsi is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment," Fennec Chief Executive Officer Jeff Hackman said Friday in a statement.
Price: 5.89, Change: +0.05, Percent Change: +0.86
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.